FDA Puts Stronger Warning on Invokana, Invokamet Due to Kidney Risks
The warning labels on four diabetes drugs are being strengthened The Fatal Effect of Invokana. The warning labels on four diabetes drugs are being strengthened due to the risk of acute kidney injury. The U.S. Food and Drug Administration (FDA) is strengthening warnings on canagliflozin, sold under the brand names Invokana … [Read more...]
Invokana Increases Risk of Bone Fractures, FDA Warns
The Food and Drug Administration (FDA) issued a safety announcement in September warning patients and health care providers of an increased risk of bone fractures in patients taking the type 2 diabetes drugs Invokana and Invokamet (canagliflozin). The FDA deemed the new safety announcement necessary because bone fractures have … [Read more...]
FDA Warns about Bone Fracture Risks with Invokana
The Food and Drug Administration (FDA) has updated the warning label of the type 2 diabetes drug canagliflozin (Invokana, Invokamet) to warn about the increased risk of bone fractures and reduced bone mineral density for those taking canagliflozin. This warning comes soon after an FDA warning in May in which the agency said … [Read more...]
Patients Taking Invokana and Invokamet Face Increased Risk
patients taking Invokana and Invokamet face increased bone fracture risk Fracture Risk Associated With Invokana and Invokamet. Diabetes patients taking the drugs Invokana and Invokamet (canagliflozin) face increased bone fracture risk, the Food and Drug Administration (FDA) warned in a recent safety communication issued last … [Read more...]
Patients Taking Invokana and Invokamet Face Increased Risk
an increased risk of bone fracture Diabetes Patients Taking Invokana Are Facing Greater Risk. The Food and Drug Administration (FDA) is advising people taking canagliflozin (Invokana, and Invokamet) that they face an increased risk of bone fracture, as reported in their latest study. The FDA has raised the warning on its … [Read more...]
FDA Warns of Increased Bone Fracture Risk for Diabetes Patients Taking Invokana and Invokamet
Last week, the Food and Drug Administration (FDA) issued a safety communication providing information on bone fracture risk and decreased bone density in patients taking the diabetes drugs Invokana and Invokamet (canagliflozin). The FDA has strengthened the warning for the type 2 diabetes medication canagliflozin (Invokana, … [Read more...]
